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Background: Hereditary hearing loss (HL) can originate from mutations in one of many genes involved in the
complex process of hearing. Identification of the genetic defects in patients is currently labor intensive and
expensive. While screening with Sanger sequencing for GJB2 mutations is common, this is not the case for the
other known deafness genes (> 60). Next generation sequencing technology (NGS) has the potential to be much
more cost efficient. Published methods mainly use hybridization based target enrichment procedures that are time
saving and efficient, but lead to loss in sensitivity. In this study we used a semi-automated PCR amplification and
NGS in order to combine high sensitivity, speed and cost efficiency.
Results: In this proof of concept study, we screened 15 autosomal recessive deafness genes in 5 patients with
congenital genetic deafness. 646 specific primer pairs for all exons and most of the UTR of the 15 selected genes
were designed using primerXL. Using patient specific identifiers, all amplicons were pooled and analyzed using the
Roche 454 NGS technology. Three of these patients are members of families in which a region of interest has
previously been characterized by linkage studies. In these, we were able to identify two new mutations in CDH23
and OTOF. For another patient, the etiology of deafness was unclear, and no causal mutation was found. In a fifth
patient, included as a positive control, we could confirm a known mutation in TMC1.
Conclusions: We have developed an assay that holds great promise as a tool for screening patients with familial
autosomal recessive nonsyndromal hearing loss (ARNSHL). For the first time, an efficient, reliable and cost effective
genetic test, based on PCR enrichment, for newborns with undiagnosed deafness is available.
Keywords: Deafness, Next generation sequencing, PCR based enrichment, Genetic diagnosticsBackground
Hearing loss (HL) is the most common birth defect in
industrialized countries and the most prevalent sensori-
neural disorder. One out of every 500 newborns has bi-
lateral permanent sensorineural HL of more than 40 dB
HL [1]. It is estimated that in developed countries, gen-
etic causes are responsible in at least two-thirds of pre-
lingual cases. In most of the cases there are no clinical* Correspondence: Paul.Coucke@UGent.be
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distribution, and reproduction in any mediumabnormalities other than the hearing loss (i.e. nonsyn-
dromic hearing loss, NSHL). Inherited NSHL is mono-
genic, with over 100 mapped loci and 46 causally
implicated genes [2].
GJB2 mutations are the most frequent cause of auto-
somal recessive non-syndromic hearing loss (ARNSHL)
and account for about 20 % of the cases [3]. Therefore,
newborns that are diagnosed with severe-to-profound HL
in the absence of other abnormal findings on physical
examination are analyzed for mutations in the GJB2 gene.
In some cases, when imaging of the inner ear shows ab-
normalities such as an enlarged vestibular aquaduct, theentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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hardly any other gene that is routinely analyzed in DNA
diagnostics. For this reason, a positive result is only
obtained in less than 20 % of deaf children for which DNA
diagnostics is requested [4]. While substantial progress has
been made in recent years in identifying the responsible
deafness genes, the key challenge lies in determining which
gene is responsible in a patient. Sequencing of all genes by
traditional DNA sequencing technology is labor intensive
and not cost effective [5].
Recently the next generation DNA sequencing tech-
nology has come of age [6]. Companies such as Roche
(454 Genome Sequencer FLX), Applied Biosystems
(Solid System) and Illumina (Genome Analyzer) have
brought high throughput DNA sequencers to the market
that can sequence several hundred million to a few bil-
lions of basepairs in a few days. Until now, this technol-
ogy has mainly been used for research purposes. Several
genes for hearing loss have been identified using this
technology [7] [8]. Most likely, the identification of other
as yet unidentified deafness genes will follow. On the
other hand, applications in DNA diagnostics in general
are still rare. A first genetic test encompassing the NSHL
genes using massively parallel sequencing technology
has been described [5] [9]. In these studies, an array-
based enrichment approach was used on a limited num-
ber of patients. Although this new technology holds the
promise to significantly reduce the cost and workload
per sample, the enrichment used leads to a significant
loss in sensitivity, which is deemed unacceptable accord-
ing to current standards using PCR amplification. Array
based enrichment procedures inherently suffer fromTable 1 Analyzed genes
Gene Number of exons Number of mutations worldwide** Number o
GJB2 2 > 220
SLC26A4 21 43
MYO15A 66 28
OTOF 48 26
CDH23 69 21
TMC1 24 20
TMPRSS3 13 16
TECTA 23 10
TRIOBP 24 9
TMIE 4 8
PJVK 7 7
ESPN 13 6
PCDH15 33 5
ESRRB 12 5
MYO7A 49 5
(*) Homopolymer repeats ≥ 6 located in the exons +/− 10 bp.
(**) Reference: [4].incomplete selection for two reasons. Firstly, due to the
presence of repetitive sequences, not all fragments can
be included in the selection set. Secondly, hybridization
based enrichment suffers from selection bias and uneven
capture efficiency. Much deeper sequencing will be
needed to ensure complete or sufficient coverage of the
selected fragments, in comparison to unbiased selection
techniques such as PCR. In combination, these factors
lead to a reduced sensitivity, while sensitivity require-
ments for DNA diagnostics are generally required to be
very high. Here, we report the evaluation of a PCR based
enrichment strategy followed by a 454 NGS approach
for 5 patients using NGS implicated in ARNSHL.Results
Five patients with familial congenital deafness were
screened for 15 deafness genes on the 454 Genome Se-
quencer in order to evaluate if next generation sequencing
enables the detection of mutations. Three of these patients
are members of families in which a region of interest has
previously been characterized by linkage studies. There-
fore, mutations in respectively CDH23 (for patients 1 and
2) and OTOF (for patient 4) were expected. In patient 5, a
known mutation (c.236+ 1 G>A) in TMC1 had to be
confirmed. For patient 3, no mutation was known.
We chose the Roche 454 next generation sequencing
platform because of the longer read lengths (up to
400 bp) of the pyrosequencing approach. We decided to
screen the 15 most important autosomal recessive deaf-
ness genes, selected on their reported mutation fre-
quency [4] (Table 1). By limiting the number of genes tof homopolymer repeats* in CDS Function in hearing process
0 ion homeostasis
7 ion homeostasis
8 hair bundle, motor protein
4 exocytose at auditory ribbon synapse
4 hair bundle, adhesion protein
4 unknown function
3 unknown function
2 extracellular matrix protein
7 hair bundle, cytoskeletal formation
0 unknown function
3 signaling of hair cells and neurons
1 hair bundle, cytoskeletal formation
8 hair bundle, adhesion protein
1 transcription factor
5 hair bundle, motor proteins
Figure 2 Cq values for the 15 genes. The Cq values for the
amplicons covering all of the 15 genes are displayed. One amplicon
of the TRIOBP gene failed during this PCR (red).
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single sequencing run [10].
The enrichment protocol prior to the sequencing was
based on an individual PCR amplification of all ampli-
cons covering the coding region of the 15 genes. A pre-
requisite to use this PCR approach is that the reaction
conditions for all the amplicons are uniform, enabling a
semi-automated workflow by using 384-well plates and
liquid handling robots. In a pilot experiment, we
designed 162 forward and reversed primers for the cod-
ing regions of OTOF and CDH23, using our in-house
developed primer design software package primerXL, in
order to evaluate the uniformity of the reaction condi-
tions. Amplification was performed on normal genomic
DNA (Roche diagnostics) and all amplicons, except 3,
could be amplified. An average Cq of 27 was obtained
(Figure 1). The 3 failed amplicons were redesigned. Sub-
sequently, primers were designed for the coding regions
of the remaining 13 genes. In the end, a set of 646 pri-
mer pairs covering all the coding sequences and most of
the UTRs of the 15 deafness genes in our setup was
developed (Figure 2).
In the next step, the patients’ DNA samples were amp-
lified. Initially, the PCRs for patients 1, 2 and 3 were per-
formed. These patients were analyzed with the standard
chemistry on a full PicoTiterPlate using 2 large regions
(Table 2). The total number of reads after filtering and
mapping was 325.272, with an average read length of
250 bp. The resulting mean coverage was 221x (patient
1), 168x (patient 2) and 194x (patient 3). Approximately
95 % of the screened amplicons had a coverage above
38, which makes them available for variant analysis
(Table 2) [10]. As such high average coverage is not ne-
cessary for reliable variant analysis; the next run was
modified accordingly.
For patients 4 and 5, 1/5 of the capacity of a Standard
run with 2-lane gasket was used for each patient. TheFigure 1 Cq values for OTOF and CDH23. The Cq value is
displayed in function of the corresponding amplicon for the OTOF
and CDH23 gene. The plot shows a drop-out of two amplicons (red).average coverage was lower than expected and therefore
an additional Titanium run (1/12) was performed to
have extra reads (Table 2), resulting in an average total
coverage of 73 and 88 for respectively patient 4 and pa-
tient 5 (Table 2).
A novel missense mutation in CDH23 could be
identified for patients 1 and 2, a result that is in
agreement with the convincing linkage data previ-
ously found (data not shown). Both are homozygous
for c.5527 G > T resulting in an amino acid substitu-
tion from Asp to Tyr at position p.1843 in exon 43.
The mutation was found in 241 reads out of 241
and in 101 reads out of 101 for patient 1 and 2 re-
spectively. Subsequently, the mutation was confirmed
with Sanger sequencing. The mutation is classified
as probably damaging by Polyphen, is not tolerated
by SIFT (Table 3) and was not reported before, nor
as disease causing mutation nor as a SNP. The mu-
tation was analyzed in the whole family and showed
full co-segregation with the phenotype.
In patient 3, we couldn’t identify a mutation that is un-
deniably disease causing. After filtering all the variants,
obtained with data analysis and filter settings as described
in ‘Methods’, we obtained a list of 171 variants. Ninety-
seven of these are located in the introns (further than 10
basepairs away from the exonic regions). Another set of
22 variants is located in the UTRs and are all reported as
polymorphisms. Of the 171 variants, 48 of them are previ-
ously reported as polymorphism or were identified in sev-
eral patients in the lab. Eventually, 7 unique variants
remained. Five of them are synonymous SNPs with no ef-
fect on splicing based on splice prediction programs. One
deletion (c.3636_3637del) located in the OTOF gene,
results in a frame shift (p.Phe1212fs). This mutation could
not be confirmed with Sanger sequencing (see Table 4).
The second mutation results in an amino acid substitution
in the CDH23 gene and was found in 50 out of 96 reads.
This variant is not known as a polymorphism. However,
Table 2 Sequencing results
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Number of NGS runs 1 1 1 2 2
454 experiment Standard 1/3 run Standard 1/3 run Standard 1/3 run Standard 1/5 Titanium 1/12 Standard 1/5 Titanium 1/12
Mapped reads 127980 96538 111492 24940* (Std) 24192* (Tit) 16767* (Std) 40169* (Tit)
Total average coverage 221 168 194 73* 88*
% sequenced amplicons
with coverage> 38
94.4 93.2 96.3 80.3 85.3
% sequenced amplicons
with coverage> 30
95.3 94.6 97.2 86.8 91.5
% sequenced amplicons
with coverage> 5
97.2 97.2 99.0 94.6 96.3
Mutations New mutation
found in CDH23
New mutation
found in CDH23
No mutation could
be clearly identified
New mutation found
in OTOF
Known mutation in
TMC1 confirmed
(*) The values for the average coverage for patient 4 and 5 are the total over the 2 runs (standard and titanium).
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prediction tools are not conclusive (see Table 4). No add-
itional mutation was found in the CDH23 gene. Further
evaluation of the known polymorphisms revealed a low
population frequency for 4 of them. Although all were
reported as non-pathogenic, we took a closer look at
these. One variant occurs in the TMPRSS3 gene with a
relative frequency in the reads of 1, previously reported as
rs35227181 and considered to be non-pathogenic. Also
the prediction tools didn’t classify the variant as disease
causing and therefore we considered this base change as a
rare variant. In OTOF a compound heterozygous variant
was found: c.2317 C>T (p.Arg773Cys) and c.4936 C>T
(p.Pro1646Ser). Both variants were detected with a relative
frequency of 0.5 and are predicted to be possibly dam-
aging (Table 4). The two variants were previously
described in the literature, where they were considered as
non-pathogenic [11] [12]. Another variant was found in
PCDH15 in 380 out of 381 reads. The variant is known as
rs4935502 and non-pathogenic according to dbSNP.
Nonetheless, it is regarded as probably damaging by
PolyPhen-2 and has a Grantham score of 126 (see table 4).
All the homopolymer repeats of these deafness genes
(Table 1) were reanalyzed with Sanger sequencing since
the 454 technology does not allow reliable sequencing of
repeats greater than 6. No mutation could be detected inTable 3 New variants observed in patients 1, 2 and 4
Variants Prediction (PolyP
Patient 1–2 CDH23 NM_022124.4:c.5527 G>
T Chr10(NCBI 36):g.73214678 G>T p.Asp1843Tyr
Probably damaging
Patient 4
OTOF NM_194248.2:c.3263 T >C
Chr2(NCBI 36):g.26550910 T>C p.Leu1088Pro
Possibly damaging
Source: Alamut version 1.53 (Interactive Biosoftware).this analysis. It remains possible that the mutation is
located in another deafness gene, not yet incorporated in
our set, or that patient 3 is a non-genetic deafness case.
The variant analysis of patient 4 revealed a new homo-
zygous missense mutation in the OTOF gene (exon 26:
c.3263 T>C (p.Leu1088Pro)). This mutation is in agree-
ment with linkage analysis, previously performed, sug-
gesting a disease causing mutation in the OTOF gene.
Prediction programs revealed the mutation as possibly
damaging (PolyPhen) and not tolerated (SIFT) and
therefore can most likely be considered as disease caus-
ing. The mutation was investigated in all available family
members and showed full co-segregation with the deaf-
ness. The prediction results of the novel mutations, with
the different software approaches, are listed in table 3.
In patient 5, included as a control, we could confirm the
heterozygous mutation in the TMC1 gene previously
found with Sanger sequencing, with a relative variant fre-
quency of 0.5. The mutation NM_138691.2:
c.236 + 1 G>A was found in 13 reads out of 26. This sub-
stitution is located in the donor splice site of intron 7.
Discussion
We have developed an assay to improve the molecular
diagnosis of autosomal recessive nonsyndromic hearing
loss (ARNSHL) by simultaneous sequencing of thehen-2) Prediction
(SIFT)
Prediction (AGVGD) Grantham
score ([0–215])
Not
tolerated
Most likely interfere
with function (Class C65)
160
Not
tolerated
Less likely interfere
with function (Class C0)
98
Table 4 Variants observed in patient 3
Gene Variant Relative
frequency
PolyPhen-2 SIFT AGVGD Grantham
score
Splicing Sanger
sequencing
CDH23 NM_022124.5:c.8167 G>C
Chr10(GRCh37):g.73566027 G>
C p.Val2723Leu
0.52 Possibly
damaging
Tolerated Class C0 32 Not affected /
OTOF NM_194248.2:c.3636_3637del
Chr2(NCBI36):g.26549600_26549601del
p.Phe1212fs
0.37 / / / / Frame shift
(The new
reading frame
ends in a STOP
codon 78
positions
downstream.)
Not
confirmed
NM_194248.2:c.2317 C> T
Chr2(NCBI36):g.26553877 C> T
p.Arg773Cys rs80356569
0.52 Probably
damaging
Not
tolerated
Class C25 180 Not affected Confirmed
NM_194248.2:c.4936 C> T
Chr2(NCBI36):g.26541265 C> T
p.Pro1646Ser rs17005371
0.48 Benign Not
tolerated
Class C65 74 Not affected Confirmed
PCDH15 NM_001142763.1:c.1319A>C
Chr10(NCBI36):g.55625450A>C
p.Asp440Ala rs4935502
1 Probably
damaging
Tolerated Class C0 126 Not affected Confirmed
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genes. The selected list of genes includes the most
frequently mutated recessive genes in patients with
hearing loss (Table 1). In contrast to hybridization
based capture approaches [5], we performed a PCR
based enrichment strategy for all target regions of
the 15 genes followed by sequencing with a 454
Genome Sequencer FLX. The optimization of the
PCR amplification conditions made an efficient semi-
automated high throughput processing of the many
PCR reactions feasible and straightforward. The PCR
reactions of all difficult amplicons can easily be
repeated and sequenced with the conventional Sanger
method. We are able to complete the screening in a
relatively short period of time. The adapter ligation
method (Shotgun protocol) was preferred over the
fusion primer approach for amplicon sequencing, in
order to reduce the sequencing cost and to obtain a
more efficient workflow. When screening a limited
number of genes, it is more advantageous to use
gene specific primers with the forward and reverse
adapters already incorporated in the oligo’s. For the
15 genes (646 amplicons) in our setting, the fusion
primer approach is cost prohibitive, since the adapter
sequence needs to be incorporated in every single
primer set. Therefore, the adapters were ligated in
one reaction to the pool of amplicons.
Two new mutations were discovered and a known
heterozygous mutation could be confirmed. The
depth of sequencing coverage was high (greater than
38) for over 90 % of the amplicons, indicating that
the majority of amplicons are covered sufficiently.Sanger sequencing remains indispensable to confirm
results, to analyze homopolymer regions and to se-
quence drop-out amplicons. Since this was a pilot
study, we restricted the screening to 5 patients.
However, by this approach we are able to screen 15
patients within a single Titanium run, making this
workflow cost-effective. While further validation with
a larger panel of positive controls is needed, our ap-
proach holds great promise. Although it was an ad-
vantage that the region of interest had already been
localized by linkage analysis for patients 1–2 and 4;
we believe that we would have found the mutation with-
out the knowledge of the linked region. The main reason
for this is that there were no other relevant mutations
found in the remaining 14 analyzed genes that could be
causal. The new variants that we found in CDH23 and
OTOF were homozygous with a relative frequency of 1.
These mutations in CDH23 and OTOF were only
found in respectively patients 1–2 and 4 and not in
the other analyzed deafness samples (e.g. we often did
find the same SNP’s in different patients). At the
same time, there was no doubt about the causality of
both mutations as predicted by the different software
tools.
Genetic counseling prior to analysis of genes poten-
tially revealing Usher syndrome (CDH23, PCDH15 and
MYO7A) is important and this should be explained to
parents who agree to have this type of diagnostics per-
formed for their child.
With patient 3, in whom we were not able to deter-
mine the disease causing mutation, we illustrate that the
major difficulty with this kind of analysis is the
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causing nature of the variant will not be convincing and
additional investigations as segregation in the family or
functional analysis will be essential.
Conclusions
Our data demonstrate that the use of NGS technology
holds promises as a tool for screening congenital deafness
genes. The availability of a more profound diagnostic
test compared to the actual “gene by gene” analysis ap-
proach, will provide better opportunities to identify the
disease causing mutation in patients permitting prompt
management and accurate genetic counseling. Once a
substantial number of patients originating from a spe-
cific population are analyzed, we will be able to deter-
mine the relative contribution of this set of 15 deafness
genes to recessive hearing loss in this specific popula-
tion, data which is currently unavailable. From a tech-
nical point of view, the screening can be performed
even on a sporadic case. However less positive results
will be obtained since there are a significant amount of
deafness cases caused by non-genetic factors. A contin-
ued refinement of the NGS technology will further im-
prove the sequencing accuracy and reduce the cost. At
the same time bio-informatics tools will improve. This
will be critical for the interpretation of NGS-data and
essential for the diagnostic laboratories using NGS
technology.
Methods
Patient material
Genomic DNA was obtained from five patients with con-
genital HL. Patient 1 and 2 are the probands of a consan-
guineous recessive Iranian family with at least 9 affected
members for which linkage to the CDH23 locus has been
found previously. Patient 3, a member of a Turkish fam-
ily, has congenital deafness. This patient has parents with
normal hearing and GJB2 mutations have been excluded.
Patient 4 is the proband of a consanguineous Iranian
family with recessive deafness, for which linkage to the
OTOF locus has been proven. The family had 7 affected
members. Both Iranian families were seen by a geneticist
and filled in a general clinical questionnaire. However, no
detailed audiometric or ophthalmological examinations
were performed, because the families were collected in
remote locations. Both families suffered from profound
early childhood hearing loss and no obvious signs of syn-
dromal hearing loss were noted. In patient 5, a known
mutation in the TMC1 gene was identified previously,
and this patient served as a positive control. As patient 3
was part of routine deafness screening, specific ethical
approval was not required. Both Iranian families are part
of a research project at the University of Antwerp, for
which ethical approval was obtained.Primerdesign and amplicon PCR
Fifteen autosomal recessive deafness genes were selected,
based on their reported mutation frequency (Table 1)
[4]. The genes with the highest frequency of mutations
reported in the literature were chosen. Primer design
using the in house developed primerXL pipeline (Lefever
et al., in preparation), resulted in 646 oligonucleotide
pairs covering all the coding sequences (CDS) and most
of the UTRs of the 15 genes responsible for ARNSHL.
After the first round of primer design, with the most
stringent conditions (no SNPs in primer annealing re-
gion, amplicon length between 250–350 bp, GC content
between 30 and 80 %), 97.1 % of all the regions of the 15
genes could be amplified successfully. The missing
regions were caused by systematic drop-out of some
amplicons during PCR. The primer design was opti-
mized in different steps by accepting less stringent con-
ditions; first by tolerating an increase in the number of
generated primers (for example to allow the presence of
a single SNP in the 5’ region of the primer), then by low-
ering the permitted amplicon length and finally by
slightly varying the melting temperature (Tm) of the pri-
mers. All PCR reactions are performed using the same
reaction conditions, enabling an automated workflow.
The average length across the 646 amplicons is 319 bp,
resulting in an aggregate target size of approximately
200 Kb. The primers used in this step are modified at
their 5' end with a universal M13 linker sequence. The
primer sequences were synthesized by Integrated DNA
technologies and delivered in 384-well plates as a 100 μM
stock solution (forward and reverse primer separately).
All 646 amplification reactions of the 15 genes were
carried out as singleplex PCR in two 384-well plates per
patient. A master mix for each sample was prepared and
consisted of 1x Kapa Taq buffer (Sopachem), 1 mM
MgCl2 (Roche Diagnostics), 0.12 mM dNTP’s (Invitro-
gen), 0.02 U/μl Kapa Taq polymerase (Sopachem), 0.32x
LC Green Plus (Bioké) and 25 ng gDNA per reaction.
Then, 1.25 μl of the forward/reverse primer mix (1 μM
stock solution) was added to the 8.75 μl master mix
using a Freedom EVO Tecan liquid handling robotic
workstation, resulting in a final volume of 10 μl per re-
action. The PCRs were first tested on Human Genomic
DNA (Roche diagnostics). The amplification reactions
were carried out on a C1000 real-time thermal cycler
(Bio-Rad) with following cycling conditions: 95°C-5’, 94°C-
30”, 58°C-30”, 72°C-50”; 40 cycles (+ plate read after each
one), followed by a melt curve (65°C > 95°C for 5” incre-
ment 0.5°C). The Cq value was determined and the size
of the amplified products was verified on a MultiNA
(Shimadzu Biotech). To obtain an equal representation of
every amplicon in the pool, PCR products were pooled in
an equimolar manner for each patient, based on the end-
point fluorescent values. Subsequently, 100 μl of these
Figure 3 Workflow for the PCR enrichment approach. Amplicons are equimolar pooled per patient, continuously the A and B (454) adapters
with MID are ligated to each pool of amplicons. All the patients, each tagged with a unique MID, can be pooled before proceeding to emulsion
PCR.
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Micro Kit (Roche Diagnostics). The quality of the PCR
pools was verified on an Agilent 2100 Bioanalyzer with
the DNA 1000 K chip (Agilent technologies) and the con-
centration was measured with the Quant-it Picogreen
DNA assay (Invitrogen).
Next generation sequencing
The Roche A and B adapters with a MID (Multiplex
IDentifier), were ligated to each purified pool of ampli-
cons according to the Shotgun protocol for Low Mo-
lecular Weight (LMW) samples (Manual: ‘GS FLX
Shotgun DNA Library Preparation Method Manual’ (De-
cember 2007), skipping the fragmentation step. A differ-
ent MID sequence was used for every patient (Figure 3).
Quality control of the library preparation was carried
out on a RNA 6000 pico labchip (Agilent technologies)
and concentration of the library was measured with the
Quant-it Ribogreen RNA assay (Invitrogen). Emulsion
PCR and pyrosequencing on the 454 Genome Sequencer
FLX (GS FLX) were carried out as described (Titanium
emPCR method manual, Titanium sequencing method
manual Roche).
Sanger sequencing homopolymers
We identified the homopolymer regions, defined as 6 or
more repeats of the same base, located in the exonic
regions of the 15 deafness genes (Table 1). These regions
were analyzed with the conventional Sanger sequencing
method for patient 3, since we couldn’t confirm a causal
mutation in this patient.
Data analysis
Mapping of the sequenced reads was performed by
BLAT [13], software that has been integrated in V.I.P.
(Variant Identification Pipeline) [14]. Variants were iden-
tified using the variant identification module included
into V.I.P. with filter settings: homopolymers < 7, Quality
score ≥ 30, relative variant frequency ≥ 0.35 and total
coverage ≥ 20. The novel identified variants were ana-
lyzed by Alamut version 1.53 (Interactive Biosoftware).Abbreviations
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